Status | Study |
RECRUITING |
Study Name: A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension Condition: Pulmonary Arterial Hypertension Date: 2023-11-14 Interventions: Experimental Treatment |
NOT_YET_RECRUITING |
Study Name: 129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH) Condition: Pulmonary Arterial Hypertension Date: 2023-10-23 Interventions: Each xenon dose will be limited to a volume less than 25% of a subject's total lung capacity (TLC), as is the case for all protocols currently ca |
NOT_YET_RECRUITING |
Study Name: Repurposing Valsartan May Protect Against Pulmonary Hypertension Condition: Pulmonary Arterial Hypertension Date: 2023-09-07 Interventions: Valsartan 40mg twice daily for 24 weeks. |
RECRUITING |
Study Name: A Study of Pulmonary Hypertension Peripheral Limitations Condition: Pulmonary Arterial Hypertension Date: 2023-07-20 Interventions: Aerobic training will be conducted at 30 minutes 3 times a week using brisk walking with target heart rates goals based on percentage of peak HR reser |
RECRUITING |
Study Name: A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study). Condition: Pulmonary Arterial Hypertension Date: 2023-07-13 Interventions: Dose A KER-012 (Q4W); |
NOT_YET_RECRUITING |
Study Name: Assessing the Utility of Submaximal CPET in Treatment Management of PAH Condition: Pulmonary Arterial Hypertension Date: 2023-06-29 Interventions: Submaximal Cardiopulmonary exercise test equipment |
RECRUITING |
Study Name: Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) Condition: Pulmonary Arterial Hypertension Date: 2023-06-28 Interventions: Matching capsule containing placebo |
RECRUITING |
Study Name: An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) Condition: Pulmonary Arterial Hypertension Date: 2022-12-06 Interventions: Administered by oral inhalation, using a Plastiape capsule-based dry powder inhaler. |
RECRUITING |
Study Name: Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008) (MOONBEAM) Condition: Pulmonary Arterial Hypertension Date: 2022-10-17 Interventions: SC injection every 3 weeks (Q3W) of 0.3 mg/kg.Dosage may be adjusted based on protocol-specific guidelines. |
RECRUITING |
Study Name: A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension Condition: Pulmonary Arterial Hypertension Date: 2022-09-28 Interventions: 30mcg (5 breaths) of inhaled treprostinil will be administered during the RHC procedure and patients will be initiated on outpatient inhaled treprosti |